'The mountains can drive us to madness'

December 13, 2017

A mountaineer thinks he is being pursued, starts talking nonsense or changes his route without rhyme or reason. That alpinists can suffer psychotic episodes at extreme altitudes is relatively well known, and has been frequently mentioned in mountain literature. Up to now, doctors have generally associated this with acute altitude sickness. But now, emergency medicine doctors from Eurac Research and the Medical University of Innsbruck have carried out an investigation into psychotic episodes at extreme altitudes and subjected these to systematic scientific analysis, thereby discovering a new medical entity: the isolated high-altitude psychosis. The results of the study have recently been published in the renowned medical journal Psychological Medicine.

When Jeremy S. Windsor was climbing Mount Everest in 2008, he had a very strange experience which he shared with many other extreme mountaineers. Alone in the high mountains, at a height of 8,200 m, he encountered a man called Jimmy who accompanied him all day long, spoke encouraging words to him and then disappeared without trace.

Tales like this one are frequently mentioned in Alpine literature. Katharina Hüfner, lecturer at the University Clinic in Innsbruck and Hermann Brugger, Head of the Institute of Mountain Emergency Medicine at Eurac Research have, for the first time, collected around 80 psychotic episodes taken from German mountain literature and have systematically analysed the symptoms described in them.

Up to now, doctors had attributed the "Third Man syndrome" described above, along with other acoustic, optical and olfactory hallucinations, to organic causes. They frequently occur, along with symptoms such as severe headaches, dizziness and impaired balance, as side effects of a high-altitude cerebral oedema. "In our study we found that there was a group of symptoms which are purely psychotic; that is to say, that although they are indeed linked to altitude, they cannot be ascribed to a high-altitude cerebral oedema, nor to other organic factors such as fluid loss, infections or organic diseases," is how Hermann Brugger explains the new medical entity.

The isolated high-altitude psychosis is most likely to occur at heights exceeding 7,000 m above sea-level. Researchers have only been able to speculate on the causes: it is possible that factors such as oxygen deficiency, the situation of being totally dependent on oneself and the early stages of swellings in certain areas of the brain could all be triggers for the psychosis. As far as one can deduce, the symptoms disappear completely as soon as the mountaineer leaves the danger zone and comes down from the mountain - furthermore, there does not appear to be any consequential damage. "This discovery has allowed us to make a more thorough investigation of temporary psychoses in otherwise completely healthy people, an investigation which might yield important indications for the understanding of psychiatric diseases such as schizophrenia," Katharina Hüfner continues.

The results of the study are also relevant, because the syndrome increases the risk of accidents: "It is of the utmost importance that extreme mountaineers are fully apprised of these temporary phenomena," explains Brugger. "There are probably unknown numbers of unreported accidents and deaths caused by psychoses. So as to reduce the number of such accidents, it is of the greatest importance to disseminate cognitive coping strategies which the mountaineers themselves, or with the help of their partners, can apply directly whilst on the mountain," says Hüfner in completion.

Next spring, the researchers will collaborate with Nepalese doctors by undertaking further investigations in the Himalayas. They hope to find out, inter alia, how frequently this disease occurs. "The highest mountains in the world are maddeningly beautiful," says Brugger. "It's just that we had no idea that they could actually drive us to madness as well."

Eurac Research

Related Psychosis Articles from Brightsurf:

Unravelling the origins of autoimmune psychosis
Anti-NMDAR encephalitis is an autoimmune brain illness that is often mistaken by a psychiatric disorder since it causes psychoses and other behaviour alterations.

Targeted treatment for depression could benefit patients with psychosis
Patients with early onset psychosis may benefit from treatment for depression, including with anti-depressants alongside other medication, new research shows.

Pimavanserin reduced symptoms of dementia-related psychosis in phase 3 trial
New data presented at the Alzheimer's Association International Conference indicates that pimavanserin leads to a robust reduction in the severity of psychosis symptoms during the 12 week open-label phase of the study, regardless of the underlying dementia subtype or the severity of participants' dementia.

Young people with early psychosis may not require antipsychotic medications to recover
Researchers at Orygen have found that some young people with early stage first episode psychosis (FEP) can experience reduced symptoms and improve functioning without antipsychotic medication when they are provided with psychological interventions and comprehensive case management.

NMDA receptors may link psychosis and sleep deficits
Sofya Kulikova, a researcher at HSE University in Perm, is part of an international research team that has discovered potential mechanisms that explain the sleep spindle deficit in electroencephalograms (EEG) of people with schizophrenia.

Almost half of all postpartum psychosis are isolated cases
A new research result from iPSYCH shows that 40% of the women who suffer a psychosis after giving birth -- known as postpartum psychosis - do not subsequently become ill again.

Thirty risk factors found during and after pregnancy for children developing psychosis
More than 30 significant risk factors have been identified for the development of psychotic disorders in offspring in research led by the NIHR Maudsley BRC.

A new window into psychosis
A recent study in mice led a team of researchers in Japan to believe that psychosis may be caused by problems with specialized nerve cells deep within the brain, as well as a certain kind of learning behavior.

New insight into how cannabidiol takes effect in the brains of people with psychosis
Researchers from King's College London have shown that cannabidiol (CBD) alters the brain activity in people with psychosis during memory tasks, making it more similar to the activation seen in people without psychosis during the same tasks.

Study finds 'cluster of disadvantage' behind BAME psychosis rates
Excess psychosis diagnoses amongst black and South Asian men in deprived urban areas could reflect a cluster of disadvantage in specific places, rather than individual experiences of deprivation alone, a study led by Queen Mary University of London researchers concludes.

Read More: Psychosis News and Psychosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.